Evidence map›Paper›PMID 42009828›Full record

ArticleAnnals of hematology2026

Expression and prognostic impact of CD73 in classical Hodgkin lymphoma.

Beichen Liu, Cuiying He, Haisheng Liu, Guangyu Ma, Shuo Zhang, Yan Liu, Caili Liu, Kexin Li, Yunzhe Wang, Yueping Liu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Beichen LiuDepartment of Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Cuiying HeDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Haisheng LiuDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Guangyu MaDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Shuo ZhangDepartment of Breast Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Yan LiuDepartment of Otolaryngology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Caili LiuDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Kexin LiDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Yunzhe WangDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Yueping LiuDepartment of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Meng YueDepartment of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Chang LiuDepartment of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Xiaoxiao WangDepartment of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Shaoning YinDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Zheng LiDepartment of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. lixixi616@sina.com.

Funding

the Key Project of Hebei Provincial Health and Family Planning Commission Fund 20220133
6 · The paper itself

Abstract

Relapsed or refractory classical Hodgkin lymphoma (cHL) remains a clinical challenge, underscoring the need for early identification of high-risk patients to guide treatment stratification. CD73, an ectoenzyme involved in adenosine production, plays a key role in immunosuppression and tumor progression. While elevated CD73 expression has been linked to poor prognosis in many cancers, its role in cHL has not been fully elucidated. In this retrospective case-control study, we evaluated the baseline expression of CD73, CD39, and PD-L1 in newly diagnosed cHL patients and explored their association with treatment outcomes. A total of 84 patients were followed after first-line therapy and retrospectively categorized into a relapsed/refractory (r/r) group (n = 47) and a non-r/r group (n = 37). CD73 expression was significantly lower in the r/r group compared to the non-r/r group. Patients with low CD73 expression had inferior complete response rates and shorter progression-free survival (PFS). On multivariate analysis, low CD73 expression remained an independent adverse prognostic factor for PFS (hazard ratio: 3.321, 95% CI: 1.384–7.967). These findings suggest that baseline CD73 expression may serve as a prognostic biomarker for relapse risk and long-term outcomes in cHL, with potential implications for individualized treatment strategies.

Indexed as

5'-NucleotidaseBiomarkers, TumorGene Expression Regulation, NeoplasticHodgkin DiseaseAdultAgedCase-Control StudiesFemaleGPI-Linked ProteinsHumansMaleMiddle AgedPrognosisRetrospective StudiesYoung Adult5'-NucleotidaseBiomarkers, TumorGPI-Linked ProteinsNT5E protein, humanCD73Classical Hodgkin lymphomaImmune checkpoint inhibitorPrognostic factorRelapsed/refractory lymphoma

Identifiers

PMID42009828
PMCPMC13095907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.